Innovent Biologics
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies.
Launch date
Employees
Market cap
€7.9b
Enterprise valuation
€7.1b (Public information from Sep 2024)
Share price
HKD41.8 1801.HK
Suzhou Shi Jiangsu (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.8b | 4.3b | 4.6b | 6.2b | 7.9b | 10.3b | 13.3b |
| % growth | 267 % | 11 % | 7 % | 36 % | 27 % | 30 % | 29 % |
| EBITDA | (735m) | (2.9b) | (1.8b) | (691m) | (630m) | 412m | 1.8b |
| % EBITDA margin | (19 %) | (68 %) | (39 %) | (11 %) | (8 %) | 4 % | 13 % |
| Profit | (998m) | (3.1b) | (2.2b) | (1.0b) | (860m) | 22.9m | 1.3b |
| % profit margin | (26 %) | (73 %) | (48 %) | (17 %) | (11 %) | - | 10 % |
| EV / revenue | 23.4x | 11.9x | 8.7x | 9.1x | 7.3x | 5.7x | 4.4x |
| EV / EBITDA | -122.3x | -17.5x | -22.5x | -81.7x | -91.9x | 141.6x | 32.9x |
| R&D budget | 1.9b | 2.5b | 2.9b | 2.2b | - | - | - |
| R&D % of revenue | 48 % | 58 % | 63 % | 36 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$5.0m | Series A | ||
$25.0m | Series B | ||
$115m | Series C | ||
* | $260m | Series D | |
$150m Valuation: $1.0b | Series E | ||
| N/A | $421m Valuation: $2.0b | IPO | |
* | N/A | €300m | Post IPO Equity |
| Total Funding | €505m | ||
Recent News about Innovent Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Innovent Biologics
Edit
ACQUISITION by Nuvation Bio Mar 2024